GLP‑1s can cost muscle
Experts are warning that GLP‑1 weight‑loss drugs can cause meaningful muscle loss unless users prioritize strength training and adequate protein, and there’s a related bone‑health caution that rapid weight loss can reduce bone density. ( ) The science is evolving: genetic studies suggest some people respond differently to GLP‑1s, and clinical data show roughly 10–15% of users are 'non‑responders' who do not lose at least 5% of body weight — so tailoring exercise and nutrition is now central to using these drugs safely. ( )
These drugs work by making the stomach empty more slowly and the brain feel full sooner, so people often eat a lot less without trying as hard. The catch is that a smaller calorie intake can shrink muscle as well as fat if nothing tells the body to keep that muscle. (nature.com) Muscle is not just “extra tissue.” It is the engine that helps you stand up, climb stairs, carry groceries, and burn more energy at rest than fat tissue does. (nature.com) That is why doctors are paying attention to body composition, which means what share of weight loss came from fat and what share came from lean tissue like muscle. In a body-composition substudy of the SURMOUNT-1 trial, tirzepatide users lost about 21.3% of body weight by week 72, and about 25% of that lost weight was lean mass. (onlinelibrary.wiley.com) Semaglutide trials have shown the same basic pattern: weight goes down, fat mass goes down more, but lean mass also falls. A 2024 review in Clinical Nutrition said semaglutide-linked weight loss has repeatedly been associated with decreases in lean mass as well as fat mass. (clinicalnutritionjournal.com) The warning is not that these medicines are bad at weight loss. The warning is that fast weight loss can act like a budget cut across the whole body, and muscle gets cut too unless protein intake and resistance exercise give it a reason to stay. (nature.com, msn.com) Bone has a similar problem. Bones stay stronger when they keep feeling load from body weight and exercise, and rapid weight loss reduces that loading. (nature.com) A randomized clinical trial in 195 adults found that glucagon-like peptide-1 treatment alone reduced hip and spine bone mineral density, while the group that combined the drug with exercise preserved bone mineral density at the hip, spine, and forearm despite larger weight loss. (jamanetwork.com) That makes strength training do two jobs at once. Lifting weights or doing other resistance work pulls on muscle to help keep it and loads bone to help protect it. (jamanetwork.com, nature.com) Protein matters for the same reason. If appetite is blunted by semaglutide or tirzepatide, it gets easier to undereat protein, and that leaves the body with less raw material to repair and maintain muscle. (nature.com, msn.com) The other new piece is that people do not respond the same way. A Nature study published on April 8, 2026 analyzed 27,885 people on these medicines and found genetic variants tied to both stronger weight-loss response and higher risk of nausea or vomiting. (nature.com) That helps explain why some patients lose a dramatic amount of weight while others barely move the scale. Clinical reporting has put the “non-responder” group at roughly 10% to 15% of users, usually defined as losing less than 5% of body weight. (beckershospitalreview.com, msn.com) So the new picture is less “take the shot and wait” and more “treat the drug like one part of a plan.” The safest version now looks increasingly personalized: enough protein, regular resistance training, and follow-up that tracks not just pounds lost but what kind of tissue was lost with them. (nature.com, nature.com, jamanetwork.com)
